ChemoCentryx, Inc. (NASDAQ:CCXI)

CAPS Rating: 5 out of 5

Results 1 - 7 of 7

Recs

0
Member Avatar Aurum (51.19) Submitted: 7/29/2014 12:48:33 PM : Outperform Start Price: $5.72 CCXI Score: -13.52

Part of a broader pick of micro cap biotechs with encouraging preliminary clinical trial data and significant upside.

Recs

0
Member Avatar Chemdawg (45.62) Submitted: 10/7/2013 7:03:35 PM : Outperform Start Price: $5.30 CCXI Score: -25.02

huge stock price falloff because of a Crohns diease drug? You gotta be s#itting me.....biotechs have a bright future with ACA on the horizon and this will be one of the better bets to rebound..

Recs

2
Member Avatar zzlangerhans (99.76) Submitted: 10/1/2013 4:05:02 AM : Outperform Start Price: $5.49 CCXI Score: -27.10

I'm not putting myself forth as an expert on ChemoCentryx, having lost 50% of my 12K investment on the dual failures of SHIELD-1 and CCX140. I wish I could say that was my worst fail of 2013, but both Aveo and Dynavax were substantially larger. Right now, the only thing ChemoCentryx has in their favor is a nice slug of cash, augmented by a 65M financing the company wisely conducted in April. The company states they will proceed to full enrollment in the CCX140 trial in diabetic nephropathy despite the ugly interim data, and they have a couple more chemokine compounds in clinical trials. I might have been happy to walk away from this stock without looking back, but Portefeuilkle has prevailed on me to re-establish a smaller position with 350 shares at 5.5.

Recs

0
Member Avatar sidiling (97.61) Submitted: 9/24/2013 1:27:46 PM : Outperform Start Price: $5.76 CCXI Score: -30.45

130 MM in cash with a burn rate of 10MM per quarter

Recs

0
Member Avatar TerryHoodSr (49.40) Submitted: 9/6/2013 2:16:12 PM : Outperform Start Price: $6.39 CCXI Score: -40.24

spec

Recs

0
Member Avatar 007mercucio (34.61) Submitted: 9/1/2013 10:13:19 AM : Outperform Start Price: $8.21 CCXI Score: -59.96

This stock is so oversold right now. They have 10 drugs in the pipeline. Their drug development engine algorithmically automates the development of new drug molecules. There is still a -chance- for Vercirnon, despite the recent SHIELD-1 Phase 3 study results (they are still investigating the methodology of the study). AND the stock is trending back from its recent fall. This is THE BEST time to get in on CCXI.

Recs

0
Member Avatar fatmoneyrz (97.14) Submitted: 8/24/2013 10:00:14 AM : Outperform Start Price: $11.40 CCXI Score: -77.25

My timing was terrible on this buy, still CCXI has a strong balance sheet, and many nice early stage candidates in their pipeline. I expect this goes back to its high with time.

Results 1 - 7 of 7

Featured Broker Partners


Advertisement